Previous 10 | Next 10 |
Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA PR Newswire CAMBRIDGE, Mass. , Dec. 22, 2022 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: A...
Penny Stocks To Buy According to Company Insiders In December When you think about the end of the year, tax-loss selling is a more frequently discussed topic than loading up on penny stocks . But this isn’t an average year, and penny stocks are trading in typical conditions. As you...
This article is about penny stocks under $1; they can be purchased for pennies, but does that mean they’re worth it? You can decide for yourself based on your trading strategy. This niche within the stock market today has grown in popularity over the last few months. Due to the 2022 st...
Penny Stocks Under $1 It’s another choppy session in the stock market today, but penny stocks remain a shining light for day traders. Despite the S&P, Nasdaq, and Dow taking a hiatus from a two-day recession-fueled sell-off, traders are getting back in the saddle in preparation for...
Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Nov. 22, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the...
Akebia Therapeutics, Inc. (AKBA) Q3 2022 Results Conference Call November 03, 2022 04:30 PM ET Company Participants Mercedes Carrasco - Senior Director of Corporate Communications John Butler - CEO, President and Director David Spellman - Senior VP, CFO and Treas...
Akebia press release ( NASDAQ: AKBA ): Q3 GAAP EPS of -$0.28 misses by $0.14 . Revenue of $49M (+0.5% Y/Y) beats by $1.83M . Cash and cash equivalents as of September 30, 2022 were $144.8M. Akebia believes that its cash resources will be sufficient to fund ...
Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights PR Newswire Akebia to host conference call on November 3 at 4:30 p.m. ET Filed Formal Dispute Resolution Request related to the CRL for vadadustat Report...
Akebia Therapeutics to Report Third Quarter Financial Results and Highlight Recent Company Milestones PR Newswire Akebia to Host Conference Call to Provide Business Update CAMBRIDGE, Mass. , Oct. 27, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. ...
Akebia Therapeutics Announces Poster Presentation at ASN Kidney Week 2022 PR Newswire CAMBRIDGE, Mass. , Oct. 21, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people...
News, Short Squeeze, Breakout and More Instantly...
Akebia Therapeutics Inc. Company Name:
AKBA Stock Symbol:
NASDAQ Market:
Akebia Therapeutics Inc. Website:
Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets PR Newswire Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement wit...
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference PR Newswire CAMBRIDGE, Mass. , June 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purp...
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer PR Newswire CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with t...